Spero Therapeutics, Inc. 8-K

What Happened

• Spero Therapeutics, Inc. (SPRO) filed an 8-K on June 25, 2026 reporting actions from its June 23, 2026 Annual Meeting. Stockholders approved the Spero Therapeutics, Inc. 2026 Stock Incentive Plan (the "2026 Plan") and approved an amendment to the company’s certificate of incorporation to increase authorized common stock from 120,000,000 to 240,000,000 shares. The certificate of amendment became effective upon filing with the Delaware Secretary of State on June 23, 2026. The 2026 Plan authorizes, subject to adjustments, up to 12,895,866 shares of common stock for issuance.

Key Details

• Quorum: 41,061,190 shares were present in person or by proxy (≈70.91% of 57,901,493 shares outstanding as of April 24, 2026).
• 2026 Stock Incentive Plan vote: 25,379,610 For; 3,567,416 Against; 53,384 Abstained; 12,060,780 Broker Non-Votes.
• Certificate amendment vote (increase to 240,000,000 shares): 30,356,780 For; 10,558,645 Against; 145,765 Abstained. Certificate filed and effective June 23, 2026.
• Other meeting outcomes: Milind Deshpande, Ph.D., and Kathleen Tregoning were re-elected as Class III directors; PricewaterhouseCoopers LLP was ratified as auditor; the advisory vote on executive compensation was approved. (See filing for full vote tallies.)

Why It Matters

• The approved 2026 Plan provides the company with a pool of nearly 13 million shares to grant equity awards to employees, directors and consultants, which can affect share dilution and executive incentives.
• Doubling authorized shares gives Spero flexibility to issue additional shares for compensation, financing or other corporate needs without an immediate further shareholder vote, which could affect future dilution and capital-raising options.
• Investors should note the vote margins and broker non-votes recorded at the meeting and review the full plan and amendment (exhibits) for terms that could affect share count and governance.